Varmins Chooses New Director for NIH Office of Alternative Medicine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 3
Volume 4
Issue 3

NIH chief Harold Varmus has chosen an army physician, Lt. Col. Wayne Jonas, as the new permanent director of the Office of Alternative Medicine (OAM); he will replace temporary acting director Alan Trachtenberg in July. Dr. Jonas earned his

NIH chief Harold Varmus has chosen an army physician, Lt. Col. Wayne Jonas, as the new permanent director of the Office of AlternativeMedicine (OAM); he will replace temporary acting director AlanTrachtenberg in July. Dr. Jonas earned his medical degree fromthe Bowman Gray School of Medicine, Winston-Salem, NC. He hasstudied alternative therapies such as homeopathy and electro-acupuncture,and has been a consultant to the OAM on several projects.

Recent Videos
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Related Content